lisinopril Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	1587	76547-98-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lisinopril linopril nanopril lisinopril hydrate lisinopril dihydrate anhydrous lisinopril	One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure. Molecular weight: 405.50 Formula: C21H31N3O5 CLOGP: -1.82 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 132.96 ALOGS: -3.27 ROTB: 12 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lisinopril
linopril
nanopril
lisinopril hydrate
lisinopril dihydrate
anhydrous lisinopril

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

Molecular weight: 405.50
Formula: C21H31N3O5
CLOGP: -1.82
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 132.96
ALOGS: -3.27
ROTB: 12

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	97 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	94 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.89 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	1 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	42 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1987	FDA	MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	3426.31	28.54	745	5268	7651	2344421
Completed suicide	2548.15	28.54	703	5310	20331	2331741
Drug hypersensitivity	2432.37	28.54	813	5200	45830	2306242
Toxicity to various agents	1054.32	28.54	403	5610	32351	2319721
Acute kidney injury	1054.18	28.54	387	5626	27735	2324337
Swollen tongue	891.71	28.54	232	5781	5111	2346961
Cough	852.11	28.54	347	5666	32770	2319302
Hyperkalaemia	628.34	28.54	180	5833	5713	2346359
Hypotension	627.25	28.54	278	5735	32158	2319914
Intestinal angioedema	551.71	28.54	85	5928	51	2352021
Lip swelling	432.90	28.54	129	5884	4692	2347380
Dizziness	353.88	28.54	232	5781	58433	2293639
Dyspnoea	343.28	28.54	255	5758	78478	2273594
Swelling face	339.76	28.54	127	5886	9366	2342706
Hyponatraemia	328.22	28.54	136	5877	13189	2338883
Hypertension	301.33	28.54	160	5853	27201	2324871
Cardio-respiratory arrest	297.01	28.54	114	5899	9032	2343040
Blood pressure increased	271.53	28.54	128	5885	16858	2335214
Vomiting	252.82	28.54	205	5808	71397	2280675
Drug interaction	250.90	28.54	145	5868	29018	2323054
Cardiac arrest	209.64	28.54	103	5910	14827	2337245
Nausea	209.13	28.54	225	5788	111964	2240108
Confusional state	203.80	28.54	119	5894	24225	2327847
Syncope	191.98	28.54	101	5912	16774	2335298
Renal failure	183.72	28.54	99	5914	17250	2334822
Diarrhoea	177.57	28.54	180	5833	83384	2268688
Respiratory arrest	168.71	28.54	68	5945	6110	2345962
Dysphagia	163.90	28.54	83	5930	12722	2339350
Abdominal pain	150.29	28.54	112	5901	34262	2317810
Poisoning	147.22	28.54	50	5963	2770	2349302
Dehydration	145.48	28.54	93	5920	22202	2329870
Intentional product misuse	140.68	28.54	68	5945	9421	2342651
Fatigue	139.96	28.54	160	5853	84713	2267359
Headache	126.82	28.54	148	5865	80031	2272041
Asthenia	125.60	28.54	115	5898	46811	2305261
Product complaint	124.03	28.54	50	5963	4488	2347584
Death	116.68	28.54	143	5870	81325	2270747
Product substitution issue	115.35	28.54	49	5964	5020	2347052
Pharyngeal oedema	114.84	28.54	44	5969	3449	2348623
Bradycardia	114.11	28.54	60	5953	9921	2342151
Blood creatinine increased	113.88	28.54	61	5952	10472	2341600
Blood pressure inadequately controlled	111.52	28.54	31	5982	869	2351203
Fall	108.02	28.54	106	5907	46993	2305079
Hypersensitivity	107.76	28.54	79	5934	23514	2328558
Lactic acidosis	106.48	28.54	47	5966	5283	2346789
Hypotensive transfusion reaction	104.32	28.54	15	5998	0	2352072
Respiratory distress	101.73	28.54	45	5968	5084	2346988
Inappropriate antidiuretic hormone secretion	97.64	28.54	35	5978	2274	2349798
Malaise	96.83	28.54	108	5905	55477	2296595
Rash	95.75	28.54	111	5902	59447	2292625
Obstructive airways disorder	94.44	28.54	30	5983	1343	2350729
Blood pressure decreased	92.89	28.54	51	5962	9185	2342887
Urticaria	92.60	28.54	73	5940	24188	2327884
Oligohydramnios	91.71	28.54	27	5986	933	2351139
Metabolic acidosis	88.90	28.54	43	5970	5955	2346117
Osteoarthritis	88.71	28.54	45	5968	6901	2345171
Blood potassium increased	84.32	28.54	31	5982	2165	2349907
Hypokalaemia	80.90	28.54	49	5964	10605	2341467
Myoclonus	80.61	28.54	31	5982	2452	2349620
Respiratory failure	79.72	28.54	53	5960	13475	2338597
Medication error	79.11	28.54	40	5973	6091	2345981
Throat tightness	78.66	28.54	36	5977	4400	2347672
Overdose	78.31	28.54	61	5952	19846	2332226
Speech disorder	77.11	28.54	40	5973	6424	2345648
Pancreatitis acute	77.02	28.54	34	5979	3819	2348253
Pruritus	76.75	28.54	85	5928	43255	2308817
Drug ineffective	75.69	28.54	131	5882	101493	2250579
Wheezing	74.70	28.54	39	5974	6345	2345727
Drug dispensed to wrong patient	73.71	28.54	13	6000	34	2352038
Swelling	70.67	28.54	53	5960	16297	2335775
Type 2 diabetes mellitus	69.82	28.54	27	5986	2167	2349905
Atrial fibrillation	69.43	28.54	49	5964	13719	2338353
Hypovolaemia	69.37	28.54	23	5990	1180	2350892
Labile blood pressure	69.19	28.54	16	5997	207	2351865
Stridor	69.07	28.54	20	5993	651	2351421
Tongue oedema	68.63	28.54	21	5992	829	2351243
Loss of consciousness	68.42	28.54	55	5958	18712	2333360
Mental status changes	67.89	28.54	35	5978	5547	2346525
Chest pain	67.51	28.54	65	5948	28072	2324000
Hypoxia	67.08	28.54	36	5977	6191	2345881
Renal tubular necrosis	66.84	28.54	24	5989	1566	2350506
Tenderness	66.05	28.54	25	5988	1893	2350179
Exposure via ingestion	65.90	28.54	20	5993	768	2351304
Somnolence	65.49	28.54	59	5954	23426	2328646
Renal impairment	65.46	28.54	42	5971	10050	2342022
Ascites	61.97	28.54	33	5980	5587	2346485
Spinal stenosis	61.85	28.54	22	5991	1396	2350676
Gastrooesophageal reflux disease	61.85	28.54	39	5974	9056	2343016
Anxiety	61.51	28.54	63	5950	29296	2322776
Thermohypoaesthesia	61.22	28.54	10	6003	13	2352059
Oedema peripheral	61.00	28.54	57	5956	23706	2328366
Pancreatitis	60.91	28.54	37	5976	8042	2344030
Condition aggravated	60.53	28.54	65	5948	31914	2320158
Joint swelling	58.57	28.54	48	5965	16771	2335301
Foetal methotrexate syndrome	57.41	28.54	9	6004	7	2352065
Haemodialysis	57.20	28.54	23	5990	2046	2350026
Anaphylactic reaction	57.10	28.54	38	5975	9667	2342405
Hypoglycaemia	57.04	28.54	36	5977	8371	2343701
Lymphomatoid papulosis	56.97	28.54	11	6002	54	2352018
Multimorbidity	56.68	28.54	12	6001	100	2351972
Laryngeal oedema	56.24	28.54	20	5993	1268	2350804
Dysarthria	55.73	28.54	32	5981	6270	2345802
Nodular rash	55.70	28.54	11	6002	62	2352010
Tachycardia	55.40	28.54	46	5967	16363	2335709
Weight decreased	54.27	28.54	58	5955	28313	2323759
Palpitations	53.22	28.54	45	5968	16411	2335661
Orthostatic hypotension	53.04	28.54	24	5989	2855	2349217
Abdominal tenderness	52.41	28.54	18	5995	1029	2351043
Fear of eating	52.38	28.54	9	6004	19	2352053
Sight disability	52.06	28.54	9	6004	20	2352052
Accidental overdose	51.47	28.54	26	5987	3946	2348126
Acute myocardial infarction	51.03	28.54	28	5985	5027	2347045
Abdominal pain upper	51.01	28.54	50	5963	22050	2330022
Haematemesis	50.80	28.54	26	5987	4056	2348016
Extensor plantar response	49.88	28.54	13	6000	283	2351789
Hypertensive crisis	49.65	28.54	22	5991	2491	2349581
Intentional overdose	49.56	28.54	37	5976	11284	2340788
Vision blurred	49.27	28.54	41	5972	14627	2337445
Ventricular fibrillation	49.13	28.54	21	5992	2180	2349892
Oedema mouth	48.90	28.54	16	5997	787	2351285
Acute hepatic failure	48.59	28.54	22	5991	2620	2349452
Grip strength decreased	48.39	28.54	17	5996	1040	2351032
Abdominal distension	47.76	28.54	35	5978	10376	2341696
Facial nerve disorder	47.38	28.54	10	6003	82	2351990
Circulatory collapse	47.18	28.54	24	5989	3696	2348376
Cerebral thrombosis	46.32	28.54	13	6000	377	2351695
Anaemia	46.25	28.54	59	5954	34733	2317339
Dry mouth	45.40	28.54	31	5982	8222	2343850
Chest discomfort	45.33	28.54	39	5974	14556	2337516
Adverse drug reaction	45.30	28.54	31	5982	8252	2343820
Blood pressure systolic increased	44.68	28.54	20	5993	2319	2349753
Urinary retention	44.60	28.54	23	5990	3644	2348428
Oliguria	44.24	28.54	17	5996	1340	2350732
Oedema	43.89	28.54	33	5980	10170	2341902
Pain	43.63	28.54	78	5935	61779	2290293
Therapeutic response unexpected	43.49	28.54	23	5990	3836	2348236
Hyperreflexia	43.20	28.54	15	5998	886	2351186
Amaurosis	43.06	28.54	10	6003	132	2351940
Shock	42.70	28.54	23	5990	3981	2348091
Left ventricular hypertrophy	42.62	28.54	14	5999	697	2351375
Blood sodium decreased	42.25	28.54	21	5992	3079	2348993
Hyperventilation	42.24	28.54	16	5997	1213	2350859
Choking	42.18	28.54	17	5996	1521	2350551
Myocardial infarction	41.98	28.54	42	5971	18971	2333101
Dyspepsia	40.49	28.54	31	5982	9813	2342259
Face oedema	40.21	28.54	22	5991	3926	2348146
Optic ischaemic neuropathy	40.09	28.54	11	6002	293	2351779
Blindness cortical	39.93	28.54	9	6004	103	2351969
Hypothermia	39.86	28.54	18	5995	2130	2349942
Treatment failure	39.36	28.54	27	5986	7212	2344860
Abdominal discomfort	39.34	28.54	39	5974	17417	2334655
Drug intolerance	39.27	28.54	35	5978	13682	2338390
Blood urea increased	39.26	28.54	21	5992	3584	2348488
Hyperlipidaemia	39.08	28.54	19	5994	2655	2349417
Unresponsive to stimuli	38.47	28.54	23	5990	4853	2347219
Neuromyelitis optica spectrum disorder	38.44	28.54	10	6003	216	2351856
Electrocardiogram T wave peaked	38.42	28.54	8	6005	61	2352011
Presyncope	38.20	28.54	21	5992	3782	2348290
Gastrointestinal haemorrhage	38.14	28.54	33	5980	12402	2339670
Proteinuria	37.93	28.54	19	5994	2831	2349241
Hallucination, visual	37.14	28.54	19	5994	2960	2349112
Delirium	37.01	28.54	23	5990	5200	2346872
Sinus bradycardia	36.96	28.54	17	5996	2099	2349973
Paraesthesia	36.76	28.54	42	5971	22046	2330026
Drug clearance decreased	36.41	28.54	9	6004	157	2351915
Gait disturbance	36.06	28.54	42	5971	22503	2329569
Pupillary reflex impaired	35.61	28.54	11	6002	448	2351624
Decreased appetite	35.27	28.54	47	5966	28844	2323228
Agitation	35.26	28.54	30	5983	11021	2341051
Muscular weakness	34.90	28.54	34	5979	14863	2337209
Lethargy	34.82	28.54	27	5986	8703	2343369
Laryngospasm	34.65	28.54	12	6001	703	2351369
Restlessness	34.64	28.54	21	5992	4542	2347530
Pyrexia	34.41	28.54	65	5948	53643	2298429
Cardiac murmur	34.38	28.54	15	5998	1636	2350436
Loss of personal independence in daily activities	34.17	28.54	22	5991	5289	2346783
Peripheral swelling	33.66	28.54	36	5977	17561	2334511
Myalgia	33.26	28.54	41	5972	23292	2328780
Purpura senile	33.17	28.54	6	6007	19	2352053
Rotator cuff repair	33.01	28.54	9	6004	234	2351838
Gastrointestinal disorder	32.18	28.54	26	5987	8891	2343181
Glomerulonephritis membranous	32.02	28.54	8	6005	146	2351926
Foetal exposure during pregnancy	31.93	28.54	21	5992	5231	2346841
Hypophagia	31.90	28.54	19	5994	3981	2348091
Rhabdomyolysis	31.79	28.54	23	5990	6681	2345391
Eosinophilic pneumonia	31.54	28.54	10	6003	444	2351628
Contusion	31.45	28.54	30	5983	12780	2339292
Bundle branch block left	30.91	28.54	12	6001	972	2351100
Chronic obstructive pulmonary disease	30.67	28.54	23	5990	7054	2345018
Blood glucose increased	30.58	28.54	29	5984	12261	2339811
Tremor	30.57	28.54	37	5976	20624	2331448
Dialysis	30.48	28.54	15	5998	2152	2349920
Salivary gland enlargement	30.45	28.54	7	6006	88	2351984
Dyspnoea exertional	30.30	28.54	21	5992	5699	2346373
Feeling abnormal	29.76	28.54	39	5974	23542	2328530
Hypoaldosteronism	29.52	28.54	6	6007	40	2352032
Hypovolaemic shock	29.43	28.54	11	6002	803	2351269
Cardiac failure congestive	29.15	28.54	32	5981	16069	2336003
Nodal rhythm	28.98	28.54	9	6004	373	2351699
Macroglossia	28.83	28.54	7	6006	113	2351959

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Angioedema	18099.98	38.20	3529	6543	6135	1730574
Hyperkalaemia	2726.40	38.20	764	9308	7783	1728926
Completed suicide	2499.31	38.20	829	9243	15483	1721226
Acute kidney injury	2307.15	38.20	955	9117	33989	1702720
Hypotension	1489.67	38.20	671	9401	28983	1707726
Swollen tongue	1202.19	38.20	318	9754	2490	1734219
Lip swelling	1042.65	38.20	284	9788	2511	1734198
Cough	932.86	38.20	426	9646	18771	1717938
Drug hypersensitivity	873.08	38.20	379	9693	14756	1721953
Toxicity to various agents	808.64	38.20	442	9630	28699	1708010
Swelling face	664.88	38.20	224	9848	4259	1732450
Wheezing	558.86	38.20	193	9879	3960	1732749
Dyspnoea	470.57	38.20	394	9678	51665	1685044
Anaphylactic reaction	427.45	38.20	176	9896	5937	1730772
Syncope	421.97	38.20	226	9846	13943	1722766
Dizziness	406.21	38.20	305	9767	34056	1702653
Dysphagia	403.79	38.20	197	9875	9971	1726738
Bradycardia	347.39	38.20	180	9892	10354	1726355
Blood creatinine increased	345.16	38.20	197	9875	13749	1722960
Dehydration	319.54	38.20	204	9868	17454	1719255
Intentional overdose	284.58	38.20	142	9930	7528	1729181
Blood potassium increased	269.59	38.20	99	9973	2431	1734278
Pharyngeal oedema	266.10	38.20	88	9984	1565	1735144
Blood urea increased	247.82	38.20	111	9961	4600	1732109
Orthostatic hypotension	240.30	38.20	99	9973	3332	1733377
Hypovolaemia	195.49	38.20	65	10007	1175	1735534
Metabolic acidosis	194.32	38.20	98	9974	5304	1731405
Shock	190.38	38.20	89	9983	4072	1732637
Lactic acidosis	184.34	38.20	93	9979	5036	1731673
Drug interaction	180.82	38.20	176	9896	27782	1708927
Cardiac arrest	177.69	38.20	137	9935	15793	1720916
Hypertension	176.07	38.20	148	9924	19300	1717409
Urticaria	174.28	38.20	122	9950	12119	1724590
Respiratory arrest	172.97	38.20	93	9979	5746	1730963
Renal failure	170.31	38.20	147	9925	19870	1716839
Rash	164.49	38.20	195	9877	38498	1698211
Hyponatraemia	162.49	38.20	104	9968	8896	1727813
Overdose	161.33	38.20	132	9940	16569	1720140
Renal tubular necrosis	154.63	38.20	63	10009	2056	1734653
Dysphonia	153.26	38.20	73	9999	3482	1733227
Asthenia	146.07	38.20	174	9898	34496	1702213
Cardio-respiratory arrest	142.52	38.20	97	9975	9196	1727513
Pancreatitis	137.06	38.20	86	9986	7101	1729608
Fall	135.55	38.20	149	9923	27065	1709644
Vomiting	130.62	38.20	173	9899	38142	1698567
Pruritus	129.46	38.20	135	9937	23087	1713622
Blood pressure increased	125.33	38.20	95	9977	10658	1726051
Speech disorder	119.64	38.20	67	10005	4481	1732228
Pancreatitis acute	117.93	38.20	64	10008	4023	1732686
Swelling	114.36	38.20	76	9996	6920	1729789
Suicide attempt	113.04	38.20	77	9995	7304	1729405
Nausea	111.02	38.20	187	9885	51009	1685700
Laryngeal oedema	110.14	38.20	39	10033	857	1735852
Diarrhoea	107.99	38.20	190	9882	53662	1683047
Renal impairment	107.77	38.20	92	9980	12222	1724487
Hypophagia	107.16	38.20	57	10015	3440	1733269
Electrocardiogram T wave peaked	105.81	38.20	25	10047	113	1736596
Hypersensitivity	99.59	38.20	82	9990	10362	1726347
Poisoning	97.07	38.20	48	10024	2484	1734225
Respiratory distress	96.50	38.20	61	10011	5096	1731613
Intestinal angioedema	95.61	38.20	19	10053	28	1736681
Stridor	92.38	38.20	30	10042	501	1736208
Pulmonary oedema	92.13	38.20	65	10007	6521	1730188
Drooling	91.99	38.20	33	10039	754	1735955
Respiratory failure	85.56	38.20	87	9985	14418	1722291
Obstructive airways disorder	85.47	38.20	34	10038	1040	1735669
Hypoglycaemia	81.99	38.20	67	10005	8371	1728338
Throat tightness	81.77	38.20	37	10035	1565	1735144
Confusional state	76.87	38.20	99	9973	21179	1715530
Chest pain	75.64	38.20	95	9977	19819	1716890
Oral allergy syndrome	75.31	38.20	13	10059	2	1736707
Loss of consciousness	74.87	38.20	82	9990	14793	1721916
Product substitution issue	74.61	38.20	44	10028	3242	1733467
Oropharyngeal pain	73.11	38.20	50	10022	4768	1731941
Hypotensive transfusion reaction	72.94	38.20	13	10059	5	1736704
Tongue oedema	72.71	38.20	26	10046	588	1736121
Hypoxia	72.34	38.20	54	10018	5909	1730800
Oedema peripheral	70.19	38.20	81	9991	15469	1721240
Mental status changes	69.24	38.20	53	10019	6022	1730687
Fatigue	68.66	38.20	152	9920	50629	1686080
Oropharyngeal swelling	67.11	38.20	18	10054	147	1736562
Renal tubular acidosis	66.93	38.20	21	10051	312	1736397
Presyncope	66.21	38.20	38	10034	2660	1734049
Intentional product misuse	64.38	38.20	55	10017	7303	1729406
Treatment noncompliance	62.86	38.20	47	10025	5154	1731555
Dysarthria	62.40	38.20	47	10025	5212	1731497
Lip oedema	61.61	38.20	23	10049	590	1736119
Cardiogenic shock	58.72	38.20	34	10038	2420	1734289
Blood pressure decreased	58.57	38.20	53	10019	7593	1729116
Hypokalaemia	58.54	38.20	49	10023	6325	1730384
Odynophagia	56.89	38.20	23	10049	734	1735975
Electrocardiogram QRS complex prolonged	56.37	38.20	23	10049	752	1735957
Oedema	54.87	38.20	49	10023	6899	1729810
Electrocardiogram change	53.60	38.20	16	10056	199	1736510
Nodular rash	53.23	38.20	11	10061	22	1736687
Agitation	50.68	38.20	58	10014	10968	1725741
Product complaint	50.46	38.20	31	10041	2459	1734250
Medication error	48.88	38.20	39	10033	4704	1732005
Blood creatine increased	46.59	38.20	20	10052	744	1735965
Haemodialysis	46.57	38.20	30	10042	2586	1734123
Hypovolaemic shock	46.42	38.20	21	10051	887	1735822
Oedema mouth	44.77	38.20	16	10056	361	1736348
Face oedema	44.60	38.20	28	10044	2308	1734401
Tachycardia	44.37	38.20	58	10014	12570	1724139
Acute myocardial infarction	44.32	38.20	48	10024	8539	1728170
Rhabdomyolysis	43.81	38.20	54	10018	11036	1725673
Lymphomatoid papulosis	42.87	38.20	11	10061	74	1736635
Dialysis	41.39	38.20	27	10045	2377	1734332
Mouth swelling	41.18	38.20	14	10058	271	1736438
Blood pressure inadequately controlled	40.55	38.20	17	10055	596	1736113
Contraindicated product administered	39.93	38.20	22	10050	1422	1735287
Acidosis	39.19	38.20	22	10050	1475	1735234
Muscular weakness	39.03	38.20	49	10023	10200	1726509
Paraesthesia	38.27	38.20	49	10023	10402	1726307

Pharmacologic Action:

Source	Code	Description
ATC	C09AA03	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BA03	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics
ATC	C09BB03	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
ATC	C10BX07	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS HMG CoA reductase inhibitors, other combinations
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D020011	Protective Agents
CHEBI has role	CHEBI:35674	antihypertensive agent

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Myocardial infarction	indication	22298006	DOID:5844
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Superficial Ocular Infection	indication
Diabetic retinopathy	off-label use	4855003	DOID:8947
Atrial fibrillation	off-label use	49436004	DOID:0060224
Blepharoconjunctivitis	off-label use	68659002	DOID:2456
Dacryocystitis	off-label use	85777005	DOID:9938
Corneal ulcer	off-label use	91514001	DOID:8463
Diabetic renal disease	off-label use	127013003
Bacterial conjunctivitis	off-label use	128350005	DOID:9700
Acute scleroderma renal crisis	off-label use	236503001
Meibomianitis	off-label use	309779001
Infective blepharitis	off-label use	312219000
Bacterial keratitis	off-label use	314557000
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Migraine Prevention	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Jaundice	contraindication	18165001
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Immunosuppression	contraindication	38013005
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Syndrome of inappropriate vasopressin secretion	contraindication	55004003	DOID:3401
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Aortic valve stenosis	contraindication	60573004	DOID:1712
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Liver function tests abnormal	contraindication	166603001
Hypomagnesemia	contraindication	190855004
Acute hepatic failure	contraindication	197270009
Acute pancreatitis	contraindication	197456007	DOID:2913
Hypertrophic cardiomyopathy	contraindication	233873004	DOID:11984
Disease of liver	contraindication	235856003	DOID:409
Disorder of electrolytes	contraindication	237840007
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Azotemia	contraindication	445009001
Hemodialysis with High-Flux Membrane	contraindication
Intestinal Angioedema	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.18	acidic
pKa2	3.18	acidic
pKa3	11.0	Basic
pKa4	6.95	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	METHOD OF TREATING HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	METHOD OF TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	TREATMENT OF HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10039800	Nov. 6, 2035	TREATMENT OF MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	METHOD OF TREATING HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	METHOD OF TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	TREATMENT OF HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	10406199	Nov. 6, 2035	TREATMENT OF MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	METHOD OF TREATING HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	METHOD OF TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	TREATMENT OF HEART FAILURE
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	TREATMENT OF HYPERTENSION
1MG/ML	QBRELIS	SILVERGATE PHARMS	N208401	July 29, 2016	RX	SOLUTION	ORAL	9616096	Nov. 6, 2035	TREATMENT OF MYOCARDIAL INFARCTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	8.92		WOMBAT-PK	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		Ki	7.29		CHEMBL

External reference:

ID	Source
4019380	VUID
N0000147537	NUI
C0065374	UMLSCUI
D00362	KEGG_DRUG
108575001	SNOMEDCT_US
4019380	VANDF
000658	NDDF
44066	MMSL
29046	RXNORM
386873009	SNOMEDCT_US
4985	MMSL
d00732	MMSL
CHEMBL419213	ChEMBL_ID
CHEMBL1237	ChEMBL_ID
DB00722	DRUGBANK_ID
E7199S1YWR	UNII
83915-83-7	SECONDARY_CAS_RN
LPR	PDB_CHEM_ID
CHEBI:6503	CHEBI
D017706	MESH_DESCRIPTOR_UI
CHEMBL1729579	ChEMBL_ID
5362119	PUBCHEM_CID
6360	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PRINIVIL	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0019	TABLET	5 mg	ORAL	NDA	18 sections
PRINIVIL	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0106	TABLET	10 mg	ORAL	NDA	18 sections
PRINIVIL	HUMAN PRESCRIPTION DRUG LABEL	1	0006-0207	TABLET	20 mg	ORAL	NDA	18 sections
Lisinopril with Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0143-1262	TABLET	10 mg	ORAL	ANDA	12 sections
Lisinopril with Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0143-1263	TABLET	20 mg	ORAL	ANDA	12 sections
Lisinopril with Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0143-1264	TABLET	20 mg	ORAL	ANDA	12 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1266	TABLET	5 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1267	TABLET	10 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1268	TABLET	20 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-1270	TABLET	40 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9713	TABLET	20 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9714	TABLET	10 mg	ORAL	ANDA	17 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9715	TABLET	5 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0025	TABLET	2.50 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0101	TABLET	10 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0102	TABLET	20 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0103	TABLET	30 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0104	TABLET	40 mg	ORAL	ANDA	17 sections
Lisinopril and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0152	TABLET	20 mg	ORAL	ANDA	13 sections
Lisinopril and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0173	TABLET	20 mg	ORAL	ANDA	13 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0602	TABLET	2.50 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0605	TABLET	5 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0610	TABLET	10 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0620	TABLET	20 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0630	TABLET	30 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0640	TABLET	40 mg	ORAL	ANDA	17 sections
lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0185-5400	TABLET	5 mg	ORAL	ANDA	17 sections
Lisinopril and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	0185-7100	TABLET	10 mg	ORAL	ANDA	13 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0440-7674	TABLET	5 mg	ORAL	ANDA	13 sections
Lisinopril	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0405	TABLET	2.50 mg	ORAL	ANDA	17 sections